nach oben

Erschienen in:

22.02.2023 | Research

Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy

verfasst von: Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Kan Kishibe, Shunsuke Yasuda, Yuki Yajima, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Shohei Harabuchi, Michihisa Kono, Hidekiyo Yamaki, Risa Wakisaka, Yui Hirata-Nozaki, Kenzo Ohara, Takumi Kumai, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi, Hiroya Kobayashi

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein–Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL.

Takahara M, Kumai T, Kishibe K, Nagato T, Harabuchi Y (2021) Extranodal NK/T-cell lymphoma, nasal type: genetic, biologic, and clinical aspects with a central focus on Epstein–Barr virus relation. Microorganisms. https://doi.org/10.3390/microorganisms9071381CrossRefPubMedPubMedCentral

Nagato T, Takahara M, Harabuchi Y (2020) Ulcerated lesions of the midline gingiva and soft palate. Am J Med Sci 360:77. https://doi.org/10.1016/j.amjms.2020.03.012CrossRefPubMed

Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T (1990) Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128–130. https://doi.org/10.1016/0140-6736(90)90002-mCrossRefPubMed

Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S (1996) Nasal T-cell lymphoma causally associated with Epstein–Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer 77:2137–2149CrossRefPubMed

Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, Kishibe K, Harabuchi Y, Klein E (2012) Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 130:48–58. https://doi.org/10.1002/ijc.25969CrossRefPubMed

Takahara M, Nagato T, Komabayashi Y, Yoshino K, Ueda S, Kishibe K, Harabuchi Y (2013) Soluble ICAM-1 secretion and its functional role as an autocrine growth factor in nasal NK/T cell lymphoma cells. Exp Hematol 41:711–718. https://doi.org/10.1016/j.exphem.2013.03.009CrossRefPubMed

Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y (2014) Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma. Am J Hematol 89:25–33. https://doi.org/10.1002/ajh.23570CrossRefPubMed

Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y (2019) Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Lab Investig 99:612–624. https://doi.org/10.1038/s41374-018-0182-9CrossRefPubMed

Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H (2017) Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 66:877–890. https://doi.org/10.1007/s00262-017-1987-xCrossRefPubMed

10.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P (2015) CD70: an emerging target in cancer immunotherapy. Pharmacol Ther 155:1–10. https://doi.org/10.1016/j.pharmthera.2015.07.007CrossRefPubMed

11.

Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, de Haard H, Smits E, Pauwels P, Jacobs J (2022) The CD70–CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41:12. https://doi.org/10.1186/s13046-021-02215-yCrossRefPubMedPubMedCentral

12.

Croft M (2009) The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9:271–285. https://doi.org/10.1038/nri2526CrossRefPubMedPubMedCentral

13.

Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA (2009) Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 229:216–231. https://doi.org/10.1111/j.1600-065X.2009.00774.xCrossRefPubMed

14.

Ruf M, Mittmann C, Nowicka AM, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P (2015) pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clin Cancer Res 21:889–898. https://doi.org/10.1158/1078-0432.CCR-14-1425CrossRefPubMed

15.

Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62:2592–2599PubMed

16.

Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J (2013) Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol 190:6250–6258. https://doi.org/10.4049/jimmunol.1300022CrossRefPubMed

17.

Yoshino K, Kishibe K, Nagato T, Ueda S, Komabayashi Y, Takahara M, Harabuchi Y (2013) Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol 160:331–342. https://doi.org/10.1111/bjh.12136CrossRefPubMed

18.

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. Hematol J 1:53–66. https://doi.org/10.1038/sj.thj.6200013CrossRefPubMed

19.

Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, Hermans C, Smits E, Van Schil P, Lardon F, Deschoolmeester V, Pauwels P (2015) Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget 6:13462–13475. https://doi.org/10.18632/oncotarget.3880CrossRefPubMedPubMedCentral

20.

Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, Shimizu N, Tateno M, Harabuchi Y (2005) Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 11:8250–8257. https://doi.org/10.1158/1078-0432.CCR-05-1426CrossRefPubMed

21.

Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H (2020) Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology 10:1856545. https://doi.org/10.1080/2162402X.2020.1856545CrossRefPubMedPubMedCentral

22.

Kumai T, Nagato T, Kobayashi H, Komabayashi Y, Ueda S, Kishibe K, Ohkuri T, Takahara M, Celis E, Harabuchi Y (2015) CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunol Immunother 64:697–705. https://doi.org/10.1007/s00262-015-1675-7CrossRefPubMedPubMedCentral

23.

Niedobitek G, Fahraeus R, Herbst H, Latza U, Ferszt A, Klein G, Stein H (1992) The Epstein–Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 62:55–59. https://doi.org/10.1007/BF02899665CrossRefPubMed

24.

Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B (2018) Signaling by the Epstein–Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses. Proc Natl Acad Sci U S A 115:E686–E695. https://doi.org/10.1073/pnas.1713607115CrossRefPubMedPubMedCentral

25.

van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA (1993) Expression and release of CD27 in human B-cell malignancies. Blood 82:3430–3436CrossRefPubMed

26.

Nilsson A, de Milito A, Mowafi F, Winberg G, Bjork O, Wolpert EZ, Chiodi F (2005) Expression of CD27–CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 33:1500–1507. https://doi.org/10.1016/j.exphem.2005.10.005CrossRefPubMed

27.

Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O’Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP (2008) CD27–CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 112:4683–4689. https://doi.org/10.1182/blood-2007-04-084525CrossRefPubMedPubMedCentral

28.

Ishii H, Ogino T, Berger C, Kochli-Schmitz N, Nagato T, Takahara M, Nadal D, Harabuchi Y (2007) Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma. J Med Virol 79:562–572. https://doi.org/10.1002/jmv.20853CrossRefPubMed

29.

Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, Hyo R, Suzumiya J, Nakamura S, Kawa K, Oshimi K, Group NK-cTS (2011) Prospective measurement of Epstein–Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 118:6018–6022. https://doi.org/10.1182/blood-2011-05-354142CrossRefPubMed

30.

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ (2003) Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. Tumour Biol 24:53–60. https://doi.org/10.1159/000070661CrossRefPubMed

31.

Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Yamada T, Sawada M, Takahashi T, Yamada T, Seishima M, Moriwaki H, Takami T (2012) Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk Lymphoma 53:1494–1500. https://doi.org/10.3109/10428194.2012.660627CrossRefPubMed

32.

Kashima J, Okuma Y, Hosomi Y, Hishima T (2019) High serum soluble CD27 level correlates with poor performance status and reduced survival in patients with advanced lung cancer. Oncology 97:365–372. https://doi.org/10.1159/000502441CrossRefPubMed

33.

Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC (2012) Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 72:6119–6129. https://doi.org/10.1158/0008-5472.CAN-12-0588CrossRefPubMedPubMedCentral

34.

Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH (2005) Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 65:5428–5438. https://doi.org/10.1158/0008-5472.CAN-04-4395CrossRefPubMed

35.

Diegmann J, Junker K, Loncarevic IF, Michel S, Schimmel B, von Eggeling F (2006) Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 8:933–938. https://doi.org/10.1593/neo.06451CrossRefPubMedPubMedCentral

36.

Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ, Ansell SM (2014) TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin’s lymphoma. Leukemia 28:1872–1884. https://doi.org/10.1038/leu.2014.84CrossRefPubMedPubMedCentral

37.

Kitajima S, Lee KL, Fujioka M, Sun W, You J, Chia GS, Wanibuchi H, Tomita S, Araki M, Kato H, Poellinger L (2018) Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells. Oncotarget 9:19123–19135. https://doi.org/10.18632/oncotarget.24919CrossRefPubMedPubMedCentral

38.

Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005) Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 4:2037–2044. https://doi.org/10.1158/1535-7163.MCT-05-0253CrossRefPubMed

39.

Baba M, Okamoto M, Hamasaki T, Horai S, Wang X, Ito Y, Suda Y, Arima N (2008) Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol 82:3843–3852. https://doi.org/10.1128/JVI.02013-07CrossRefPubMedPubMedCentral

40.

Balsas P, Veloza L, Clot G, Sureda-Gomez M, Rodriguez ML, Masaoutis C, Frigola G, Navarro A, Bea S, Nadeu F, Gine E, Lopez-Guillermo A, Martinez A, Ribera-Cortada I, Engel P, Quintanilla-Martinez L, Klapper W, Campo E, Amador V (2021) SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood 138:2202–2215. https://doi.org/10.1182/blood.2020010527CrossRefPubMedPubMedCentral

41.

Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N, Kikutani H (1999) Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science 286:300–303. https://doi.org/10.1126/science.286.5438.300CrossRefPubMed

Titel: Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy
verfasst von: Toshihiro Nagato
Hiroki Komatsuda
Ryusuke Hayashi
Miki Takahara
Kan Kishibe
Shunsuke Yasuda
Yuki Yajima
Akemi Kosaka
Takayuki Ohkuri
Kensuke Oikawa
Shohei Harabuchi
Michihisa Kono
Hidekiyo Yamaki
Risa Wakisaka
Yui Hirata-Nozaki
Kenzo Ohara
Takumi Kumai
Akihiro Katada
Tatsuya Hayashi
Yasuaki Harabuchi
Hiroya Kobayashi
Publikationsdatum: 22.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2023
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-023-03394-7

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy

Abstract

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2023

Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma

Cancer immunity and immunotherapy beyond COVID-19

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia

CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data

The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie